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Abstract
Background: High-intensity focused ultrasound (HIFU) is considered to be an alternative to surgery. Extracorporeal
ultrasound-guided HIFU (USgFU) has been clinically used to treat solid tumors. Preliminary trials in a small sample of a
Western population suggested that this modality was safe. Most trials are performed in China thereby providing
comprehensive data for understanding the safety profile. The aim of this study was to evaluate adverse events of USgFU
therapy.
Methods and Findings: Clinical data were searched in 2 Chinese databases. Adverse events of USgFU were summarized and
compared with those of magnetic resonance-guided HIFU (MRgFU; for uterine, bone or breast tumor) and transrectal
ultrasound-guided HIFU (for prostate cancer or benign prostate hyperplasia). USgFU treatment was performed using 7 types
of device. Side effects were evaluated in 13262 cases. There were fewer adverse events in benign lesions than in malignant
lesions (11.81% vs. 21.65%, p,0.0001). Rates of adverse events greatly varied between the disease types (0–280%,
p,0.0001) and between the applied HIFU devices in both malignant (10.58–44.38%, p,0.0001) and benign lesions (1.67–
17.57%, p,0.0001). Chronological analysis did not demonstrate a decrease in the rate of adverse events. Based upon
evaluable adverse events, incidences in USgFU were consistent with those in MRgFU or transrectal HIFU. Some side effects
frequently occurred following transrectal HIFU were not reported in USgFU. Several events including intrahepatic
metastasis, intraoperative high fever, and occlusions of the superior mesenteric artery should be of particular concern
because they have not been previously noted. The types of adverse events suggested that they were ultrasonic lesions.
Conclusion: The frequency of adverse events depended on the location of the lesion and the type of HIFU device; however,
side effects of USgFU were not yet understood. USgFU did not decrease the incidence of adverse events compared with
MRgFU.
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Introduction
High intensity focused ultrasound (HIFU) is a noninvasive
therapeutic modality against solid lesions that is guided by
magnetic resonance (MRgFU) or ultrasound imaging. Moreover,
HIFU can be used as an alternative to surgery. Because ultrasound
provides a rapid imaging technique, it may be possible to monitor
tissue responses in real time using ultrasound-guided HIFU,
thereby decreasing untoward lesions [1,2]. MRgFU has been
approved by the FDA for the treatment of uterine fibroids.
Furthermore, it has been preliminarily tested in bone and breast
cancers [3,4]. Transrectal ultrasound-guided HIFU for prostate
cancer has been approved in Europe and clinical trials are
currently on-going in many countries [5].
Extracorporeal ultrasound-guided HIFU (USgFU) was clinically
introduced as a treatment for solid tumors in the late 1990 s [6].
USgFU therapy has been approved in China, and clinical trials for
cancers of liver, kidney and pancreas are in underway in Europe
and Asia. Preliminary trials for liver and kidney cancers in the
United Kingdom demonstrated the safety of USgFU; moreover, in
those trials, adverse events (AE) such as discomfort, skin toxicity
and edema at the treatment site, and mild fever were transitory
[7,8]. The small number of cases involved limits the clinical
implications. Complications in 79 cases of liver and 35 cases of
pancreas cancer in a Korean clinical center were recently
summarized. All patients had local skin reactions (redness, edema
and pain). Severe AEs, such as rib/vertebra necrosis, hydrothorax,
pancreatitis, biliary obstruction, and fistula formation did occur
[9]. The data indicate that the safety profile of USgFU treatment is
an important concern.
Most clinical trials of USgFU have been performed in China.
Over 20000 patients with malignant or benign diseases have
received this treatment, providing sufficient data to thoroughly
document the prevalence of treatment-related AEs. However,
those results are commonly published in Chinese and are
unavailable for scientists outside China. Some data have been
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e26110recently released in English, but these reports only described a few
disease types in a few clinical centers, hardly reflecting the scope of
the safety profile [10,11].
AEs following USgFU were summarized in this study.
Incidences of AEs following USgFU were compared with those
following MRgFU (uterine, bone, and breast tumors) or transrectal
HIFU (prostate cancer and benign prostate hyperplasia). The
findings indicated that the rate of AEs drastically varied between
disease types and between HIFU devices. Several events should be
of particular concern, because they have not been previously
noted.
Methods
Ethics statement
All clinical trials examined in the present report were approved
by the appropriate Institutional Review Boards and all patients
signed consent forms, both of which were stated in the original
articles. Thus, approval for the present retrospective study by an
Institutional Review Board was not needed.
Searching clinical trials
Published clinical reports of USgFU were searched in 2
databases, the Chinese Scientific & Technical Periodicals Data-
base (www.cqvip.com) and China National Knowledge Infrastruc-
ture (www.cnki.net), using the terms ‘‘high intensity focused
ultrasound’’ or ‘‘focused ultrasound’’. The inclusion criterion was
that AEs were quantitatively described in the article. Local
reactions at the treatment site (mild skin symptoms and tolerable
pain) and mild fever were not considered, as they occurred in
almost all cases [9,10].
Statistics
Data were processed with the statistics software SAS (SAS Inst.,
Cary, NC). Chi-square test was used and correct for multiple
comparison using a bootstrap method. p,0.05 was considered
significance.
For the statistical comparisons, references 3, 4 and 12 served as
the control reports for MRgFU, and references 5, 13 and 14 as the
control reports for transrectal HIFU.
Results
General
686 articles involving 23601 patients with malignant/benign
tumors and nontumorous diseases that occurred before December
2010 were identified in 2 databases. AEs were quantitatively
described in 348 articles; thus only 13262 (56.19%) cases were
included in the evaluation of side effects. HIFU treatments were
performed using 7 kinds of devices (Table 1).
Complications were multifarious. Incidences of AEs varied
considerably between the disease types (0–280%, p,0.0001), and
the rate in benign lesions was less than that in malignant lesions
(11.81% vs. 21.65%, p,0.0001) (Tables S1, S2, S3, S4, S5, S6, S7).
AEs in malignant diseases
AEs associated with 6 common cancers were summarized in
Table 2.
Liver. 777 AEs (26 types) were observed in 2201 cases (35.30%).
The most frequent event was a burn (22.99%), which occurred in
boththepre-(skin/rib/chestwall)andpost-focal(vertebra)regionsof
HIFU beams. HIFU resulted in the deterioration of liver function
(3.77%), hydrothorax (2.59%), severe abdomen pain (1.77%),
gastroenteric dysfunction (1.00%), cholecystitis (0.23%), cholangiec-
tasis (0.23%),cardiac events (0.55%), hydropericardium (0.09%) and
hematuria (0.36%). Serious AEs included tumor or vessel rupture,
intrahepatic metastasis, lung embolism, renal failure and death.
Pancreas. 150 AEs (11 types) were reported in 1717 patients
(8.74%). Burns were reported in 3.09% of the cases. Pancreatitis
(1.86%) and diabetes (1.28%) were the specific toxicities. HIFU
occasionally led to bleeding, occlusion of the superior mesenteric
artery and hepatic abscess.
Bone. 9 kinds of complications were reported, with an overall
rate of 20.54%. Frequent AEs were nerve injury (6.25%), skin
burn (4.46%) and fracture (4.46%). Tumor rupture, epiphyseal
separation and hemoglobinuria were detected in some patients.
Breast. Burns were the only reported AE, with a rate of
11.38%.
Soft tissues. The rate of AEs (burn, cutaneous necrosis and
nerve injury) was 14.81%.
Prostate. 5 types of AEs were reported. The rates of skin burn,
hematuria, urinary obstruction, urethral stricture and incontinence
were 7.20%, 17.33%, 2.40%, 1.07% and 0.53%, respectively.
Rates of AEs differed among these 6 disease types (p,0.0001)
and the highest rate occurred in liver cancer (Figure 1).
AEs in benign diseases
AEs in the treatment of uterine fibroid or prostate hyperplasia
were summarized in Table 2.
Uterine fibroid. 563 AEs (8 types) were detected in 5526
patients (10.19%). The most frequent AEs were burn (2.44%),
hematuria (2.88%), nerve injury (3.06%), and severe or prolonged
abdominal pain (1.66%).
Prostate hyperplasia. The rate of AEs was 24.80%,
including hematuria (17.78%), urinary irritation (4.30%) and
urine retention (2.72%).
Table 1. Ultrasound-guided HIFU devices and the sample size in the clinical trial.
Device Case (included/all) Frequency (MHz) Highest intensity (W/cm
2) Manufacturer
2000 94/363 1.0 $1000 Shenzhen Xifukang Med. Treatment Technol. Co.
2001 775/1890 1.0 2000 Shanhai Jiaoda Shiye Co.
CZ-901 343/560 0.8 N/A Mianyang Sonic Electronic
FEP-BY 6827/12139 0.8/1.0 4000 Beijing Yuande Biomed. Eng. Co.
HY2900 31/31 N/A $10000 Wuxi Haiying Electronic Med. System Co.
JC 2296/4005 0.8/0.9/1.0/1.6 20000 Chongqing Haifu Technol. Co.
NIT-9000 2896/4613 1.0 3000 Shanghai A&S Sci. Technol. Development Co.
doi:10.1371/journal.pone.0026110.t001
Safety Profile of USgFU
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Disease Case Adverse event Incidence
Malignant
Liver 2201 Skin burn 493 35.30% (777/2201)
Rib injury 7
Chest wall injury 2
Vertebra injury 4
Severe abdomen pain 39
ALT/AST elevation 81
Jaundice aggravation 2
Cholecystitis 5
Intrahepatic cholangiectasis 5
Gastroenteric dysfunction 22
Rupture of esophageal varices 1
Supraventricular tachycardia/palpitation 12
Hydropericardium 2
Hypertension 8
Bleeding/liquefaction 7
Tumor rupture 2
Intrahepatic metastasis 7
Lung embolism 2
Hydrothorax 57
Pneumonedema 1
Asthma 2
Hematuria 8
Creatine elevation 2
Renal failure 1
High fever 4
Death 1
Pancreas 1717 Burn 51 8.74% (150/1717)
Vertebra burn 2
Diabetes 22
Jaundice aggravation 10
Pancreatitis 32
Steatorrhea 13
Gastroenteric dysfunction 13
Bleeding 2
Occlusion of the superior mesenteric artery 1
Collapse 3
Hepatic abscess 1
Bone 224 Skin burn 10 20.54% (46/224)
Nerve injury 14
Infection 2
Fracture 10
Epiphyseal separation 1
ALP elevation 5
Hemoglobinuria 1
Tumor rupture 2
Death 1
Breast 167 Skin burn 19 11.38% (19/167)
Soft tissues 81 Skin burn 5 14.81% (12/81)
Cutaneous necrosis 4
Safety Profile of USgFU
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uterine fibroid (p,0.0001) (Figure 1).
AEs among the therapeutic devices
Of the 13262 cases, 6827 (51.48%) were treated with the device
FEP-BY, 2896 (21.84%) with the device NIT-9000, 2296 (17.31%)
with the device JC, 775 (5.84%) with the device 2001, 343 (2.59%)
with the device CZ-901, 94 (0.71%) with the device 2000, and 31
(0.23%) with the device HY2900 (Table 1).
Rates of AEs differed between therapeutic devices in both
malignant (10.58–44.38%, p,0.0001) and benign diseases (1.67–
17.57%, p,0.0001). Large variabilities in the disease type and the
case number made it impossible to perform a comprehensive
comparison. Uterine fibroid was the only disease treated with all of
Disease Case Adverse event Incidence
Nerve injury 3
Prostate 375 Skin burn 27 28.53% (107/375)
Hematuria 65
Urinary obstruction 9
Urethral stricture 4
Incontinence 2
Benign
Uterine fibroid 5526 Skin burn 112 10.19% (563/5526)
Vertebra burn 23
Nerve injury 169
Severe/prolonged abdomen pain 92
Hematuria 159
Urinary irritation 1
Hemafecia 1
Gastroenteric dysfunction 6
Prostate hyperplasia 883 Hematuria 157 24.80% (219/883)
Urinary irritation 38
Urine retention 24
ALT: alanine aminotransferase, AST: aspartate aminotransferase, ALP: alkaline phosphatase.
doi:10.1371/journal.pone.0026110.t002
Table 2. Cont.
Figure 1. Comparison of AEs among 6 malignant and 2 benign disease types. Pancr: pancreas; Soft T: soft tissues; Uterine: uterine fibroid;
Prost: prostate; BPH: benign prostate hyperplasia.
doi:10.1371/journal.pone.0026110.g001
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There were differences in the rates of AEs in cancers of liver (0–
53.29%, p,0.0001) and pancreas (0–23.26%, p,0.0001) among
the FEP-BY, JC, NIT-9000 and 2001 devices. The rates of AEs in
prostate hyperplasia (11.86–26.40%, p=0.0236) varied among the
FEP-BY, NIT-9000 and 2001 devices. Rates of AEs were
consistent in cancers of bone (7.69–21.57%, p=0.3779), soft
tissues (0–17.78%, p=0.6191) and prostate (25.30–35.87%,
p=0.1448). In breast cancer, the JC device did not lead to more
AEs compared with the NIT-9000 device (15.15% vs. 5.88%,
p=0.0542) (Figure 2A–H, Tables S1, S2, S3, S4, S5, S6, S7).
Chronological incidence of AEs
Rates of AEs were calculated chronologically. The date of
HIFU treatment was not described in some articles, so the
chronological analysis here was based upon the year of
publication. Rates of AEs over time differed in the malignant
disease, slightly varied in the benign disease, and no trend towards
reduced rates over time was detected (Figure 3).
Comparison with MRgFU for uterine fibroid and bone/
breast cancer
USgFU treatment for uterine fibroid was compared with MRgFU
treatment. Neurotoxicity was the AE that could be evaluated. Rates
of neurological events were 7.34% in MRgFU and 4.72% (including
severe abdomen pain) in USgFU (p=0.2374) [12].
In the management of breast cancer, skinburn wasdetected in1/
30 patients treated with MRgFU, and the rate was 11.38% in
USgFU treated patients (p=0.3102) [4]. A multicenter trial did not
demonstrate device-related side effects in the palliative treatment of
bone metastasis with MRgFU [3]. The rate of AEs was 20.54% in
treatment of bone cancer using USgFU (p=0.0003), including
burn, nerve injury, fracture, tumor rupture and death.
Comparison with transrectal HIFU for prostate diseases
USgFU was compared with transrectal HIFU for prostate
diseases. Rates of AEs were 28.53% in cancer and 24.80% in
benign hyperplasia, which were consistent with those in transrectal
HIFU [5,13,14]. Incidences of hematuria, the only comparable AE
in benign hyperplasia, were 17.78% and 9.6% for the USgFU and
transrectal HIFU treatments, respectively (p=0.1757) [13]. How-
ever,themostfrequentAEsfollowingtransrectalHIFUwereurinary
incontinence (6–27%) and erectile dysfunction (50–77%) in patients
with prostate cancer and hematospermia (20%) in benign hyper-
plasia, these rates were not reported for USgFU treatment [13,14].
Discussion
The location of the disease as a determinant of AEs
The types of AEs measured indicated that they were
engendered by ultrasonic lesions. HIFU therapy requires the
application of heat and cavitation, which may produce AEs [1,2].
Burn and visceral perforation suggest thermal lesions. Tumor/
vessel rupture or bleeding, ectopic embolism and intrahepatic
spread result from cavitation. Cavitation detaches cancer cells/
emboli from the primary site and thereby releases them into the
circulation, leading to metastasis or embolism [15,16]. Indeed,
most of AEs may be related to the combination of heat and
cavitation. Cavitation increases the sensitivity of tissue to heat,
thereby extending lesions beyond the HIFU focus [17]. Severe
events may be induced if vital structures are in the vicinity of the
lesion.
The present data indicated that AEs frequently occurred in
tissues adjacent to the target lesion and lying in the travel path of
the HIFU beams (i.e., the occurrence of untoward lesions
depended on the location of the lesion). Thus, selecting a proper
delivery path for the HIFU beams in vivo improves the safety
Figure 3. Chronological analysis of the rate of AEs. No trend over time towards a reduction in the rate was detected in either the malignant or
benign disease types.
doi:10.1371/journal.pone.0026110.g003
Figure 2. Comparison of AEs that occurred following treatment with different therapeutic devices. All diseases examined (A), cancers of
liver (B), pancreas (C), bone (D), soft tissues (E) and prostate (F), uterine fibroid (G) and benign prostate hyperplasia (H).
doi:10.1371/journal.pone.0026110.g002
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lower than that in the pre-focal region, for ultrasound attenuates
exponentially over distance traveled in tissues; thereby the post-
focal region may be at a lower risk of developing AEs. However,
the distribution of vertebra (in liver, pancreas and uterine tumors),
kidney (in liver cancer) and nerve injuries (in uterine fibroid)
demonstrated that ultrasonic lesions can occur in the post-focal
regions. These injuries may be caused by the refocusing of
ultrasound beams in tissues [18]. This refocusing may lead to
lesions in distant tissues. For example, refocusing may cause
arrhythmias or hydropericardium when the patient was being
treated for liver cancer. The behavior of ultrasound in tissues is
difficult to predict, which is further complicated by the
heterogeneity of biological tissues. A longer travel distance of
HIFU beams from the transducer to a target lesion indicates a
more complex ultrasound-tissue interaction, thereby increasing the
risk of inducing untoward effects.
Intrahepatic metastasis was observed in patients that were
treated for liver cancer [19]. This is inconsistent with previous
assertions that HIFU does not enhance cancer metastasis [1,2].
The failure to detect unaffected cancerous tissues during HIFU
treatment may play an important role. Tumor rupture, which
sometimes occurred, may be involved in the formation of
metastasis [20]. Rupture of esophageal varices after HIFU
occurred in some cases [21,22]. HIFU destroyed the shunt vessels,
thereby increasing the risk of angiorrhexis by increasing the
intravascular pressure. The delivery of abundant ultrasonic energy
into the body over short periods of time led to a rapid rise of body
temperature (up to 39.2uC), which overwhelmed the capacity of
body to modulate heat. Ultrasound-induced overheating can be
alleviated by suspending insonation or decreasing the intensity
[23,24]. Thus, body heat should be closely monitored when the
treatment includes high intensities or longer exposure durations.
Diabetes was a serious toxicity when treating pancreas cancer
with USgFU, with an incidence of 50% on occasion [19].
Surrounding tissues are usually covered during cancer treatment
with HIFU [18]. Some islets are therefore destroyed directly.
Moreover, the scattering of HIFU beams within the pancreas
reduces the function of b cells, because a nonlethal level of
insonation can modulate the cellular function [25]. These two
factors lead to diabetes via decreasing the yield of insulin.
Pancreatitis is mediated by similar mechanisms.
Peripheral nerve injuries have been observed following
treatment of cancers of bone and soft tissues, which can be
reversible or irreversible [26]. The prognosis depends on the type
of lesion. Irreversible damage may result from focal lesions
(including the refocusing of HIFU in tissues) when the nerve trunk
lies in the focus of the HIFU beams. Much lower energy passes
through the beams of ultrasound scattering, thereby inducing
reversible damage. Hydrothorax, cholecystitis, and gastroenteric
dysfunctions may also be due to HIFU scattering.
Ischiadic or sacral nerve damages and hematuria were the most
frequent AEs following the treatment of uterine fibroid. Insonation
harms the bladder, thereby inducing hematuria. Ischiadic and
sacral nerves lie behind the focus of the HIFU beams, and their
lesions are usually mediated by HIFU scattering and can recover
in most cases [27].
The rate of AEs in malignant diseases was higher than that in
benign ones. The reasons for this may include: (1) cancers usually
require radical ablations (i.e., destroying both the lesion and any
tissue that is definitely adjacent to the lesion), thereby yielding a
higher probability of inducing unexpected tissue damages [18].
Indeed, the deterioration of liver function in liver cancer, and the
fracture and epiphyseal separation in bone cancer are related to
the destruction of surrounding noncarcinous tissues; (2) chemo-
therapy or radiotherapy is usually undertaken perioperatively to
improve the therapeutic efficacy even though it does not always
augment HIFU effectiveness, which impairs noncarcinous tissues
and thereby increases their sensitivity to HIFU scattering [18,28];
(3) a lesion includes critical structures that cannot be avoided when
directing the travel path of HIFU beams. This was observed in
patients with occlusion of the superior mesenteric artery [29].
However, previous investigations indicate that a major vessel
cannot be damaged by HIFU, because of heat transfer by blood
flow [30]. Occlusion of an artery may result in necrosis of normal
tissues supplied by this vessel, which must be considered.
Rates of AEs varied between disease types and a higher value
(.20%) occurred following the treatment of liver, bone or prostate
disease. As such, the location of a disease plays an important role.
A lesion with more vulnerable structures in the vicinity has a
higher incidence of untoward events, and more vital structures
nearby suggest a higher risk of serious AEs. The pathological type
of a disease may not be a critical determinant of AEs.
The therapeutic device as a determinant of AEs
Theoretically, comparing AEs between treatments with different
therapeutic devices should be conducted under identical HIFU
intensity/frequency and insonation parameters. However, those
parameters varied considerably in the literature, even for the
treatment of a single disease type. HIFU works in the range of
nonlinear acoustics, and biologic responses vary drastically
between tissues types and individuals [31]. Accordingly, to ablate
a volume completely, the intensity needs to be modulated
constantly in HIFU exposure according to tissue responses [18].
These show that HIFU therapy is not a standardized procedure,
with a low level of evidence from the perspective of evidence-based
medicine, and that the therapeutic device is a determinant of the
rate of AEs. However, control trials that explore the relationship
between AEs and HIFU devices are difficult. The present data
therefore should only be used as a reference for identifying the
impact of HIFU device on AEs.
Because ultrasonography is a rapid imaging technique, it may
be possible to monitor tissue responses in real time during USgFU
treatment [2]. It is possible, therefore, that USgFU may decrease
the rate of AEs compared with MRgFU. This hypothesis was not
supported by the present data. USgFU was limited by the lower
resolution of its ultrasonic images and the use of diagnostic
ultrasounds with lower frequency (3.0–4.0 MHz; for observing
deeper tissues). The specificity and negative predictive values were
low when using ultrasonic images to predict tissue necrosis in real
time (i.e., sometimes destroyed tissues cannot be identified) [32].
This may result in longer insonation durations that allow for the
induction of untoward tissue lesions. Tissues beyond the scope of
the diagnostic ultrasound but in the propagation path of the
therapeutic beams (i.e., the blind field) are at a high risk of being
harmed by HIFU [18]. This may contribute to ultrasonic lesions
that were formed in ribs/chest wall in patients being treated for
liver cancers.
AEs in USgFU were compared with those in MRgFU and
transrectal HIFU. During treatments of uterine fibroid, AEs
observed following USgFU were likely HIFU-related, but most
AEs following MRgFU (discomfort, pain, and gynecologic/
cardiovascular/respiratory symptoms) were likely not related to
the treatment [12]. Urinary incontinence, erectile dysfunction, and
hematospermia frequently occurred in patients being treated for
prostate diseases with transrectal HIFU [13,14]. Those AEs were
not reported following USgFU, and the difference cannot be
accounted for by the physical and/or medical profiles. A
Safety Profile of USgFU
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the clinical trials using USgFU. AEs mentioned in those trials
included in this study were almost events that occurred soon after
the treatment, and later complications were unavailable in the
published data. AEs resulted from USgFU treatment, therefore,
remain to be thoroughly described.
USgFU is not a standardized therapeutic process. An optimal
insonation regime depends on the experience of an operation
team, thereby increasing the probability of over- or under-
sonication. Over-sonication may extend the lesion to nontarget
tissues, and under-sonication may result in residual intact tissues
that facilitate cancer relapse and metastasis. Ultrasound should be
delivered into the lesion in a few seconds to realize tissue ablation.
A higher intensity favors the energy deposition within the target
volume [18]. This also increases the intensity within tissues outside
the focus increasing the risk of untoward lesions. A HIFU device
employing a higher intensity therefore has a higher incidence of
AEs–the highest rate of AEs occurred following treatments with
the device JC in the present data. It is reasonable to expect that
AEs may be reduced with the development of HIFU devices and
greater clinical experiences. However, chronological analysis did
not demonstrate a trend towards a reduction in the rates of AEs
over time. USgFU modality, therefore, is still at an early stage.
Limitations and summary
The case number varied drastically between disease types and
between HIFU devices, and the disease types treated differed
among HIFU devices. These limited a systemic evaluation of AEs;
thus AEs can only be compared in some disease types between
some HIFU devices in this study. The insonation parameter and
mode were not described detailedly in literatures, so their impacts
on AEs cannot be deduced. The safety of therapeutic modalities
should be compared in a specific cohort. However, AEs of
MRgFU or transrectal HIFU were from a Western population for
lack of the data in a Chinese population, which was another
limitation.
In summary, AEs following USgFU treatment were not yet
thoroughly understood. Side effects were dependent upon the
location of the lesion and the HIFU device used in its treatment.
High incidences of AEs in some disease types indicated that the
use of USgFU therapy should be curtailed in some cases. Indeed,
USgFU therapy should be restricted to carefully selected cases.
Rigid guidelines should be developed to calibrate and monitor the
use of HIFU devices because AEs were related to the therapeutic
device.
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